<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27300434</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>04</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1878-3686</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Jun</Month>
              <Day>13</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer cell</Title>
          <ISOAbbreviation>Cancer Cell</ISOAbbreviation>
        </Journal>
        <ArticleTitle>YAP/TAZ at the Roots of Cancer.</ArticleTitle>
        <Pagination>
          <StartPage>783</StartPage>
          <EndPage>803</EndPage>
          <MedlinePgn>783-803</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ccell.2016.05.005</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1535-6108(16)30210-0</ELocationID>
        <Abstract>
          <AbstractText>YAP and TAZ are highly related transcriptional regulators pervasively activated in human malignancies. Recent work indicates that, remarkably, YAP/TAZ are essential for cancer initiation or growth of most solid tumors. Their activation induces cancer stem cell attributes, proliferation, chemoresistance, and metastasis. YAP/TAZ are sensors of the structural and mechanical features of the cell microenvironment. A number of cancer-associated extrinsic and intrinsic cues conspire to overrule the YAP-inhibiting microenvironment of normal tissues, including changes in mechanotransduction, inflammation, oncogenic signaling, and regulation of the Hippo pathway. Addiction to YAP/TAZ thus potentially represents a central cancer vulnerability that may be exploited therapeutically.</AbstractText>
          <CopyrightInformation>Copyright © 2016 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zanconato</LastName>
            <ForeName>Francesca</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine, University of Padua School of Medicine, viale Colombo 3, 35126 Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cordenonsi</LastName>
            <ForeName>Michelangelo</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine, University of Padua School of Medicine, viale Colombo 3, 35126 Padua, Italy. Electronic address: michelangelo.cordenonsi@unipd.it.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Piccolo</LastName>
            <ForeName>Stefano</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine, University of Padua School of Medicine, viale Colombo 3, 35126 Padua, Italy. Electronic address: piccolo@bio.unipd.it.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>670126</GrantID>
            <Acronym>ERC_</Acronym>
            <Agency>European Research Council</Agency>
            <Country>International</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cancer Cell</MedlineTA>
        <NlmUniqueID>101130617</NlmUniqueID>
        <ISSNLinking>1535-6108</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000091364">Transcriptional Coactivator with PDZ-Binding Motif Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C551991">WWTR1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000091102">YAP-Signaling Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C088374">YAP1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000090683" MajorTopicYN="N">Hippo Signaling Pathway</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040542" MajorTopicYN="N">Mechanotransduction, Cellular</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015534" MajorTopicYN="N">Trans-Activators</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000091364" MajorTopicYN="N">Transcriptional Coactivator with PDZ-Binding Motif Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000091102" MajorTopicYN="N">YAP-Signaling Proteins</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>1</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>4</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>6</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>6</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27300434</ArticleId>
        <ArticleId IdType="mid">EMS79998</ArticleId>
        <ArticleId IdType="pmc">PMC6186419</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ccell.2016.05.005</ArticleId>
        <ArticleId IdType="pii">S1535-6108(16)30210-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Anakk S, Bhosale M, Schmidt VA, Johnson RL, Finegold MJ, Moore DD. Bile acids activate YAP to promote liver carcinogenesis. Cell reports. 2013;5:1060–1069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3961013</ArticleId>
            <ArticleId IdType="pubmed">24268772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonescu CR, Le Loarer F, Mosquera JM, Sboner A, Zhang L, Chen CL, Chen HW, Pathan N, Krausz T, Dickson BC, et al.  Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes, chromosomes &amp; cancer. 2013;52:775–784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4089994</ArticleId>
            <ArticleId IdType="pubmed">23737213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aragona M, Panciera T, Manfrin A, Giulitti S, Michielin F, Elvassore N, Dupont S, Piccolo S. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell. 2013;154:1047–1059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23954413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V, et al.  YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell. 2014;158:157–170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24976009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azzolin L, Zanconato F, Bresolin S, Forcato M, Basso G, Bicciato S, Cordenonsi M, Piccolo S. Role of TAZ as mediator of Wnt signaling. Cell. 2012;151:1443–1456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23245942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai H, Zhang N, Xu Y, Chen Q, Khan M, Potter JJ, Nayar SK, Cornish T, Alpini G, Bronk S, et al.  Yes-associated protein regulates the hepatic response after bile duct ligation. Hepatology. 2012;56:1097–1107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3431197</ArticleId>
            <ArticleId IdType="pubmed">22886419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baia GS, Caballero OL, Orr BA, Lal A, Ho JS, Cowdrey C, Tihan T, Mawrin C, Riggins GJ. Yes-associated protein 1 is activated and functions as an oncogene in meningiomas. Molecular cancer research : MCR. 2012;10:904–913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4703097</ArticleId>
            <ArticleId IdType="pubmed">22618028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, Fuchs CS, Magness ST, Smits R, Ogino S, et al.  Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature. 2013;493:106–110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3536889</ArticleId>
            <ArticleId IdType="pubmed">23178811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Benedetto AD, Todaro M, Stassi G, Sperati F, et al.  TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene. 2015;34:681–690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24531710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basu-Roy U, Bayin NS, Rattanakorn K, Han E, Placantonakis DG, Mansukhani A, Basilico C. Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells. Nature communications. 2015;6 6411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4429898</ArticleId>
            <ArticleId IdType="pubmed">25832504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benham-Pyle BW, Pruitt BL, Nelson WJ. Cell adhesion. Mechanical strain induces E-cadherin-dependent Yap1 and beta-catenin activation to drive cell cycle entry. Science. 2015;348:1024–1027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4572847</ArticleId>
            <ArticleId IdType="pubmed">26023140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, James JD, Gumin J, Diefes KL, Kim SH, et al.  The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes &amp; development. 2011;25:2594–2609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3248681</ArticleId>
            <ArticleId IdType="pubmed">22190458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011;17:320–329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3569482</ArticleId>
            <ArticleId IdType="pubmed">21383745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanpain C, Fuchs E. Stem cell plasticity. Plasticity of epithelial stem cells in tissue regeneration. Science. 2014;344 1242281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4523269</ArticleId>
            <ArticleId IdType="pubmed">24926024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boin A, Couvelard A, Couderc C, Brito I, Filipescu D, Kalamarides M, Bedossa P, De Koning L, Danelsky C, Dubois T, et al.  Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas. Neuro-oncology. 2014;16:1196–1209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4136892</ArticleId>
            <ArticleId IdType="pubmed">24558021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, et al.  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nature Genetics. 2016;48:407–416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26928227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression. Nat Rev Cancer. 2009;9:108–122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2649117</ArticleId>
            <ArticleId IdType="pubmed">19165226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byun MR, Hwang JH, Kim AR, Kim KM, Hwang ES, Yaffe MB, Hong JH. Canonical Wnt signalling activates TAZ through PP1A during osteogenic differentiation. Cell death and differentiation. 2014;21:854–863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4013522</ArticleId>
            <ArticleId IdType="pubmed">24510127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai J, Maitra A, Anders RA, Taketo MM, Pan D. beta-Catenin destruction complex-independent regulation of Hippo-YAP signaling by APC in intestinal tumorigenesis. Genes &amp; development. 2015;29:1493–1506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4526734</ArticleId>
            <ArticleId IdType="pubmed">26193883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai J, Zhang N, Zheng Y, de Wilde RF, Maitra A, Pan D. The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes &amp; development. 2010;24:2383–2388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2964748</ArticleId>
            <ArticleId IdType="pubmed">21041407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, Harrington K, Williamson P, Moeendarbary E, Charras G, Sahai E. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nature cell biology. 2013;15:637–646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3836234</ArticleId>
            <ArticleId IdType="pubmed">23708000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, Brummelkamp TR. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol. 2007;17:2054–2060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17980593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan LH, Wang W, Yeung W, Deng Y, Yuan P, Mak KK. Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression. Oncogene. 2014;33:4857–4866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24141783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, Zeng Q, Hong W. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 2008;68:2592–2598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18413727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan SW, Lim CJ, Loo LS, Chong YF, Huang C, Hong W. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem. 2009;284:14347–14358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2682883</ArticleId>
            <ArticleId IdType="pubmed">19324876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen D, Sun Y, Wei Y, Zhang P, Rezaeian AH, Teruya-Feldstein J, Gupta S, Liang H, Lin HK, Hung MC, Ma L. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med. 2012;18:1511–1517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3684419</ArticleId>
            <ArticleId IdType="pubmed">23001183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, Chan SW, Zhang X, Walsh M, Lim CJ, Hong W, Song H. Structural basis of YAP recognition by TEAD4 in the hippo pathway. Genes Dev. 2010;24:290–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2811830</ArticleId>
            <ArticleId IdType="pubmed">20123908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, Zhang N, Gray RS, Li H, Ewald AJ, Zahnow CA, Pan D. A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis. Genes &amp; development. 2014;28:432–437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3950341</ArticleId>
            <ArticleId IdType="pubmed">24589775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, Zhang N, Xie R, Wang W, Cai J, Choi KS, David KK, Huang B, Yabuta N, Nojima H, et al.  Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP. Genes &amp; development. 2015;29:1285–1297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4495399</ArticleId>
            <ArticleId IdType="pubmed">26109051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng H, Zhang Z, Rodriguez-Barrueco R, Borczuk A, Liu H, Yu J, Silva JM, Cheng SK, Perez-Soler R, Halmos B. Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells. Oncotarget. 2015 doi: 10.18632/oncotarget.6721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.6721</ArticleId>
            <ArticleId IdType="pmc">PMC5045371</ArticleId>
            <ArticleId IdType="pubmed">26716514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, et al.  YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene. 2016;35:1541–1553. (2016)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4695331</ArticleId>
            <ArticleId IdType="pubmed">26119935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127:469–480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17081971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, et al.  The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011;147:759–772.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22078877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, ten Hacken E, Bertilaccio MT, Antonini E, Neri A, et al.  Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med. 2014;20:599–606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4057660</ArticleId>
            <ArticleId IdType="pubmed">24813251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Da CL, Xin Y, Zhao J, Luo XD. Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions. World J Gastroenterol. 2009;15:4055–4061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2731958</ArticleId>
            <ArticleId IdType="pubmed">19705503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Das A, Fischer RS, Pan D, Waterman CM. YAP nuclear localization in the absence of cell-cell contact is mediated by a filamentous actin-dependent, myosin II- and phospho-YAP independent pathway during ECM mechanosensing. J Biol Chem. 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4813550</ArticleId>
            <ArticleId IdType="pubmed">26757814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeRan M, Yang J, Shen CH, Peters EC, Fitamant J, Chan P, Hsieh M, Zhu S, Asara JM, Zheng B, et al.  Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell reports. 2014;9:495–503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4223634</ArticleId>
            <ArticleId IdType="pubmed">25373897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Agostino S, Sorrentino G, Ingallina E, Valenti F, Ferraiuolo M, Bicciato S, Piazza S, Strano S, Del Sal G, Blandino G. YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. EMBO reports. 2015;17(2):188–201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5290815</ArticleId>
            <ArticleId IdType="pubmed">26691213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz-Martin J, Lopez-Garcia MA, Romero-Perez L, Atienza-Amores MR, Pecero ML, Castilla MA, Biscuola M, Santon A, Palacios J. Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. Endocrine-related cancer. 2015;22:443–454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25870251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diep CH, Zucker KM, Hostetter G, Watanabe A, Hu C, Munoz RM, Von Hoff DD, Han H. Down-regulation of Yes Associated Protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells. PLoS One. 2012;7:e32783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3291657</ArticleId>
            <ArticleId IdType="pubmed">22396793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130:1120–1133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2666353</ArticleId>
            <ArticleId IdType="pubmed">17889654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, et al.  Role of YAP/TAZ in mechanotransduction. Nature. 2011;474:179–183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21654799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eisinger-Mathason TS, Mucaj V, Biju KM, Nakazawa MS, Gohil M, Cash TP, Yoon SS, Skuli N, Park KM, Gerecht S, Simon MC. Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis. Proc Natl Acad Sci U S A. 2015;112:E3402–3411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4491775</ArticleId>
            <ArticleId IdType="pubmed">26080399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, Kenney AM, Brat DJ, Perry A, Yong WH, et al.  Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011;121:381–396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3519926</ArticleId>
            <ArticleId IdType="pubmed">21267586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Enzo E, Santinon G, Pocaterra A, Aragona M, Bresolin S, Forcato M, Grifoni D, Pession A, Zanconato F, Guzzo G, et al.  Aerobic glycolysis tunes YAP/TAZ transcriptional activity. The EMBO journal. 2015;34:1349–1370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4491996</ArticleId>
            <ArticleId IdType="pubmed">25796446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Errani C, Zhang L, Sung YS, Hajdu M, Singer S, Maki RG, Healey JH, Antonescu CR. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes, chromosomes &amp; cancer. 2011;50:644–653.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3264678</ArticleId>
            <ArticleId IdType="pubmed">21584898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, Zaidi MR, Ksander BR, Merlino G, Sodhi A, et al.  Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014;25:831–845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4074519</ArticleId>
            <ArticleId IdType="pubmed">24882515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandez BG, Gaspar P, Bras-Pereira C, Jezowska B, Rebelo SR, Janody F. Actin-Capping Protein and the Hippo pathway regulate F-actin and tissue growth in Drosophila. Development. 2011;138:2337–2346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21525075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandez LA, Northcott PA, Dalton J, Fraga C, Ellison D, Angers S, Taylor MD, Kenney AM. YAP1 is amplified and up-regulated in hedgehogassociated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes &amp; development. 2009;23:2729–2741.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2788333</ArticleId>
            <ArticleId IdType="pubmed">19952108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandez LA, Squatrito M, Northcott P, Awan A, Holland EC, Taylor MD, Nahle Z, Kenney AM. Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene. 2012;31:1923–1937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3583298</ArticleId>
            <ArticleId IdType="pubmed">21874045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fitamant J, Kottakis F, Benhamouche S, Tian HS, Chuvin N, Parachoniak CA, Nagle JM, Perera RM, Lapouge M, Deshpande V, et al.  YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. Cell reports. 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4565791</ArticleId>
            <ArticleId IdType="pubmed">25772357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujii M, Toyoda T, Nakanishi H, Yatabe Y, Sato A, Matsudaira Y, Ito H, Murakami H, Kondo Y, Kondo E, et al.  TGF-beta synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med. 2012;209:479–494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3302232</ArticleId>
            <ArticleId IdType="pubmed">22329991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gailite I, Aerne BL, Tapon N. Differential control of Yorkie activity by LKB1/AMPK and the Hippo/Warts cascade in the central nervous system. Proc Natl Acad Sci U S A. 2015;112:E5169–5178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4577147</ArticleId>
            <ArticleId IdType="pubmed">26324895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galli GG, Carrara M, Yuan WC, Valdes-Quezada C, Gurung B, Pepe-Mooney B, Zhang T, Geeven G, Gray NS, de Laat W, et al.  YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers. Mol Cell. 2015;60:328–337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4624327</ArticleId>
            <ArticleId IdType="pubmed">26439301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Prat L, Martinez-Vicente M, Perdiguero E, Ortet L, Rodriguez-Ubreva J, Rebollo E, Ruiz-Bonilla V, Gutarra S, Ballestar E, Serrano AL, et al.  Autophagy maintains stemness by preventing senescence. Nature. 2016;529:37–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26738589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaspar P, Tapon N. Sensing the local environment: actin architecture and Hippo signalling. Current opinion in cell biology. 2014;31:74–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25259681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>George NM, Day CE, Boerner BP, Johnson RL, Sarvetnick NE. Hippo signaling regulates pancreas development through inactivation of Yap. Mol Cell Biol. 2012;32:5116–5128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3510525</ArticleId>
            <ArticleId IdType="pubmed">23071096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gregorieff A, Liu Y, Inanlou MR, Khomchuk Y, Wrana JL. Yapdependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer. Nature. 2015;526:715–718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26503053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Y, Pan Q, Zhang J, Xu X, Liu X, Wang Q, Yi R, Xie X, Yao L, Liu W, Shen L. Functional and clinical evidence that TAZ is a candidate oncogene in hepatocellular carcinoma. Journal of cellular biochemistry. 2015;116:2465–2475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25650113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halder G, Dupont S, Piccolo S. Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat Rev Mol Cell Biol. 2012;13:591–600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22895435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S, Goode S. Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 2010;70:8517–8525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2970655</ArticleId>
            <ArticleId IdType="pubmed">20947521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han SX, Bai E, Jin GH, He CC, Guo XJ, Wang LJ, Li M, Ying X, Zhu Q. Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J Immunol Res. 2014;2014 261365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4016924</ArticleId>
            <ArticleId IdType="pubmed">24860833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harvey KF, Pfleger CM, Hariharan IK. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell. 2003;114:457–467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12941274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013;13:246–257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23467301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayashi H, Higashi T, Yokoyama N, Kaida T, Sakamoto K, Fukushima Y, Ishimoto T, Kuroki H, Nitta H, Hashimoto D, et al.  An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression. Cancer Res. 2015;75:4985–4997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26420216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He C, Mao D, Hua G, Lv X, Chen X, Angeletti PC, Dong J, Remmenga SW, Rodabaugh KJ, Zhou J, et al.  The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. EMBO Mol Med. 2015;7:1426–1449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4644376</ArticleId>
            <ArticleId IdType="pubmed">26417066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysik E, Johnson RL, Martin JF. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science. 2011;332:458–461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3133743</ArticleId>
            <ArticleId IdType="pubmed">21512031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herr KJ, Tsang YH, Ong JW, Li Q, Yap LL, Yu W, Yin H, Bogorad RL, ahlman JE, Chan YG, et al.  Loss of alpha-catenin elicits a cholestatic response and impairs liver regeneration. Scientific reports. 2014;4 6835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4213774</ArticleId>
            <ArticleId IdType="pubmed">25355493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiemer SE, Zhang L, Kartha VK, Packer TS, Almershed M, Noonan V, Kukuruzinska M, Bais MV, Monti S, Varelas X. A YAP/TAZRegulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma. Molecular cancer research : MCR. 2015;13:957–968.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4470857</ArticleId>
            <ArticleId IdType="pubmed">25794680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirata E, Girotti MR, Viros A, Hooper S, Spencer-Dene B, Matsuda M, Larkin J, Marais R, Sahai E. Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling. Cancer Cell. 2015;27:574–588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4402404</ArticleId>
            <ArticleId IdType="pubmed">25873177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu X, Xin Y, Xiao Y, Zhao J. Overexpression of YAP1 is correlated with progression, metastasis and poor prognosis in patients with gastric carcinoma. Pathol Oncol Res. 2014;20:805–811.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24643316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hua G, Lv X, He C, Remmenga SW, Rodabough KJ, Dong J, Yang L, Lele SM, Yang P, Zhou J, et al.  YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells. Oncogene. 2015 doi: 10.1038/onc.2015.288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2015.288</ArticleId>
            <ArticleId IdType="pmc">PMC4791205</ArticleId>
            <ArticleId IdType="pubmed">26364602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell. 2005;122:421–434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16096061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imajo M, Miyatake K, Iimura A, Miyamoto A, Nishida E. A molecular mechanism that links Hippo signalling to the inhibition of Wnt/beta-catenin signalling. The EMBO journal. 2012;31:1109–1122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3297994</ArticleId>
            <ArticleId IdType="pubmed">22234184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeong W, Kim SB, Sohn BH, Park YY, Park ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DS, et al.  Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Res. 2014;34:811–817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4082822</ArticleId>
            <ArticleId IdType="pubmed">24511017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X, He F, Wang Y, Zhang Z, Wang W, et al.  A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell. 2014;25:166–180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24525233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Justice RW, Zilian O, Woods DF, Noll M, Bryant PJ. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 1995;9:534–546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7698644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley LC, Yaffe MB. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. The EMBO journal. 2000;19:6778–6791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC305881</ArticleId>
            <ArticleId IdType="pubmed">11118213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanellos G, Zhou J, Patel H, Ridgway RA, Huels D, Gurniak CB, Sandilands E, Carragher NO, Sansom OJ, Witke W, et al.  ADF and Cofilin1 Control Actin Stress Fibers, Nuclear Integrity, and Cell Survival. Cell reports. 2015;13:1949–1964.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4678118</ArticleId>
            <ArticleId IdType="pubmed">26655907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang W, Tong JH, Chan AW, Lee TL, Lung RW, Leung PP, So KK, Wu K, Fan D, Yu J, et al.  Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;17:2130–2139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21346147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B, et al.  Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 2014;158:185–197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4109295</ArticleId>
            <ArticleId IdType="pubmed">24954535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DH, Kim SH, Lee OJ, Huang SM, Kwon JL, Kim JM, Kim JY, Seong IO, Song KS, Kim KH. Differential expression of Yes-associated protein and phosphorylated Yes-associated protein is correlated with expression of Ki-67 and phospho-ERK in colorectal adenocarcinoma. Histol Histopathol. 2013a;28:1483–1490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23673988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim GJ, Kim H, Park YN. Increased expression of Yes-associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular-cholangiocarcinoma. PLoS One. 2013b;8:e75449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3782432</ArticleId>
            <ArticleId IdType="pubmed">24086533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim HM, Jung WH, Koo JS. Expression of Yes-associated protein (YAP) in metastatic breast cancer. Int J Clin Exp Pathol. 2015a;8:11248–11257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4637664</ArticleId>
            <ArticleId IdType="pubmed">26617849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JH, Asthagiri AR. Matrix stiffening sensitizes epithelial cells to EGF and enables the loss of contact inhibition of proliferation. Journal of cell science. 2011;124:1280–1287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3065384</ArticleId>
            <ArticleId IdType="pubmed">21429934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim MH, Kim J, Hong H, Lee SH, Lee JK, Jung E, Kim J. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation. The EMBO journal. 2016;35:462–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4772854</ArticleId>
            <ArticleId IdType="pubmed">26668268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim NG, Koh E, Chen X, Gumbiner BM. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc Natl Acad Sci U S A. 2011;108:11930–11935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3141988</ArticleId>
            <ArticleId IdType="pubmed">21730131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SK, Jung WH, Koo JS. Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer. Int J Clin Exp Pathol. 2014;7:3224–3234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4097213</ArticleId>
            <ArticleId IdType="pubmed">25031743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim T, Yang SJ, Hwang D, Song J, Kim M, Kyum Kim S, Kang K, Ahn J, Lee D, Kim MY, et al.  A basal-like breast cancer-specific role for SRF-IL6 in YAP-induced cancer stemness. Nature communications. 2015b;6 10186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4703869</ArticleId>
            <ArticleId IdType="pubmed">26671411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koontz LM, Liu-Chittenden Y, Yin F, Zheng Y, Yu J, Huang B, Chen Q, Wu S, Pan D. The Hippo effector Yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression. Dev Cell. 2013;25:388–401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3705890</ArticleId>
            <ArticleId IdType="pubmed">23725764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes &amp; development. 2003;17:1090–1100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC196046</ArticleId>
            <ArticleId IdType="pubmed">12695331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A. 2012;109:E2441–2450.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3443162</ArticleId>
            <ArticleId IdType="pubmed">22891335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lau AN, Curtis SJ, Fillmore CM, Rowbotham SP, Mohseni M, Wagner DE, Beede AM, Montoro DT, Sinkevicius KW, Walton ZE, et al.  Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. The EMBO journal. 2014;33:468–481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3989628</ArticleId>
            <ArticleId IdType="pubmed">24497554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lavado A, He Y, Pare J, Neale G, Olson EN, Giovannini M, Cao X. Tumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap/Taz transcriptional coactivators. Development. 2013;140:3323–3334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3737715</ArticleId>
            <ArticleId IdType="pubmed">23863479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS, Kim MC, Jeong WI, Calvisi DF, Kim JM, Lim DS. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A. 2010;107:8248–8253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2889558</ArticleId>
            <ArticleId IdType="pubmed">20404163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee KW, Lee SS, Kim SB, Sohn BH, Lee HS, Jang HJ, Park YY, Kopetz S, Kim SS, Oh SC, Lee JS. Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21:357–364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4513664</ArticleId>
            <ArticleId IdType="pubmed">25388162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee MJ, Ran Byun M, Furutani-Seiki M, Hong JH, Jung HS. YAP and TAZ Regulate Skin Wound Healing. The Journal of investigative dermatology. 2014;134:518–525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24108406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Wolfe A, Septer S, Edwards G, Zhong X, Abdulkarim AB, Ranganathan S, Apte U. Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver Int. 2012;32:38–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4175712</ArticleId>
            <ArticleId IdType="pubmed">22098159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Gao E, Vite A, Yi R, Gomez L, Goossens S, van Roy F, Radice GL. Alpha-catenins control cardiomyocyte proliferation by regulating Yap activity. Circ Res. 2015a;116:70–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4282606</ArticleId>
            <ArticleId IdType="pubmed">25305307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li P, Silvis MR, Honaker Y, Lien WH, Arron ST, Vasioukhin V. alphaE-catenin inhibits a Src-YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway. Genes &amp; development. 2016;30:798–811.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4826396</ArticleId>
            <ArticleId IdType="pubmed">27013234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q, Li S, Mana-Capelli S, Roth Flach RJ, Danai LV, Amcheslavsky A, Nie Y, Kaneko S, Yao X, Chen X, et al.  The conserved misshapen-warts-Yorkie pathway acts in enteroblasts to regulate intestinal stem cells in Drosophila. Dev Cell. 2014;31:291–304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4254555</ArticleId>
            <ArticleId IdType="pubmed">25453828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li S, Yu Z, Chen SS, Li F, Lei CY, Chen XX, Bao JM, Luo Y, Lin GZ, Pang SY, Tan WL. The YAP1 oncogene contributes to bladder cancer cell proliferation and migration by regulating the H19 long noncoding RNA. Urol Oncol. 2015b;33:427 e421–410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26163939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li YW, Shen H, Frangou C, Yang N, Guo J, Xu B, Bshara W, Shepherd L, Zhu Q, Wang J, et al.  Characterization of TAZ domains important for the induction of breast cancer stem cell properties and tumorigenesis. Cell Cycle. 2015c;14:146–156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4352971</ArticleId>
            <ArticleId IdType="pubmed">25602524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z, Wang Y, Zhu Y, Yuan C, Wang D, Zhang W, Qi B, Qiu J, Song X, Ye J, et al.  The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer. Mol Oncol. 2015d;9:1091–1105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5528756</ArticleId>
            <ArticleId IdType="pubmed">25704916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang N, Zhang C, Dill P, Panasyuk G, Pion D, Koka V, Gallazzini M, Olson EN, Lam H, Henske EP, et al.  Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. J Exp Med. 2014;211:2249–2263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4203941</ArticleId>
            <ArticleId IdType="pubmed">25288394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin C, Yao E, Chuang PT. A conserved MST1/2-YAP axis mediates Hippo signaling during lung growth. Dev Biol. 2015a;403:101–113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4469623</ArticleId>
            <ArticleId IdType="pubmed">25912685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin CH, Pelissier FA, Zhang H, Lakins J, Weaver VM, Park C, LaBarge MA. Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors. Molecular biology of the cell. 2015b;26:3946–3953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4710228</ArticleId>
            <ArticleId IdType="pubmed">26337386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, et al.  The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015c;47:250–256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4930244</ArticleId>
            <ArticleId IdType="pubmed">25665005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu G, Yu FX, Kim YC, Meng Z, Naipauer J, Looney DJ, Liu X, Gutkind JS, Mesri EA, Guan KL. Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway. Oncogene. 2015;34:3536–3546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4721508</ArticleId>
            <ArticleId IdType="pubmed">25195862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu JY, Li YH, Lin HX, Liao YJ, Mai SJ, Liu ZW, Zhang ZL, Jiang LJ, Zhang JX, Kung HF, et al.  Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC Cancer. 2013a;13:349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3750259</ArticleId>
            <ArticleId IdType="pubmed">23870412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T, Liu Y, Gao H, Meng F, Yang S, Lou G. Clinical significance of yes-associated protein overexpression in cervical carcinoma: the differential effects based on histotypes. Int J Gynecol Cancer. 2013b;23:735–742.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23502453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, Li H, Rajurkar M, Li Q, Cotton JL, Ou J, Zhu LJ, Goel HL, Mercurio AM, Park JS, et al.  Tead and AP1 Coordinate Transcription and Motility. Cell reports. 2016;14:1169–1180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4749442</ArticleId>
            <ArticleId IdType="pubmed">26832411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO, Pan D. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes &amp; development. 2012;26:1300–1305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3387657</ArticleId>
            <ArticleId IdType="pubmed">22677547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Low BC, Pan CQ, Shivashankar GV, Bershadsky A, Sudol M, Sheetz M. YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth. FEBS Lett. 2014;588(16):2663–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24747426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, Wang Y, Halder G, Finegold MJ, Lee JS, Johnson RL. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A. 2010;107:1437–1442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2824398</ArticleId>
            <ArticleId IdType="pubmed">20080689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucas EP, Khanal I, Gaspar P, Fletcher GC, Polesello C, Tapon N, Thompson BJ. The Hippo pathway polarizes the actin cytoskeleton during collective migration of Drosophila border cells. The Journal of cell biology. 2013;201:875–885.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3678158</ArticleId>
            <ArticleId IdType="pubmed">23733343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mana-Capelli S, Paramasivam M, Dutta S, McCollum D. Angiomotins link F-actin architecture to Hippo pathway signaling. Molecular biology of the cell. 2014;25:1676–1685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4019498</ArticleId>
            <ArticleId IdType="pubmed">24648494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao B, Hu F, Cheng J, Wang P, Xu M, Yuan F, Meng S, Wang Y, Yuan Z, Bi W. SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene. 2014;33:1468–1474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23542177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin-Belmonte F, Perez-Moreno M. Epithelial cell polarity, stem cells and cancer. Nat Rev Cancer. 2011;12:23–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22169974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng Z, Moroishi T, Guan KL. Mechanisms of Hippo pathway regulation. Genes &amp; development. 2016;30:1–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4701972</ArticleId>
            <ArticleId IdType="pubmed">26728553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng Z, Moroishi T, Mottier-Pavie V, Plouffe SW, Hansen CG, Hong AW, Park HW, Mo JS, Lu W, Lu S, et al.  MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. Nature communications. 2015;6:8357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4600732</ArticleId>
            <ArticleId IdType="pubmed">26437443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menzel M, Meckbach D, Weide B, Toussaint NC, Schilbach K, Noor S, Eigentler T, Ikenberg K, Busch C, Quintanilla-Martinez L, et al.  In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survival. Pigment Cell Melanoma Res. 2014;27:671–673.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24703331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mo JS, Meng Z, Kim YC, Park HW, Hansen CG, Kim S, Lim DS, Guan KL. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nature cell biology. 2015;17:500–510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4380774</ArticleId>
            <ArticleId IdType="pubmed">25751140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohseni M, Sun J, Lau A, Curtis S, Goldsmith J, Fox VL, Wei C, Frazier M, Samson O, Wong KK, et al.  A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nature cell biology. 2014;16:108–117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4159053</ArticleId>
            <ArticleId IdType="pubmed">24362629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morvaridi S, Dhall D, Greene MI, Pandol SJ, Wang Q. Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis. Scientific reports. 2015;5:16759.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4645184</ArticleId>
            <ArticleId IdType="pubmed">26567630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, Akatsuka S, Horio Y, Hida T, Kondo Y, et al.  LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 2011;71:873–883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21245096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muramatsu T, Imoto I, Matsui T, Kozaki K, Haruki S, Sudol M, Shimada Y, Tsuda H, Kawano T, Inazawa J. YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis. 2011;32:389–398.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21112960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nallet-Staub F, Marsaud V, Li L, Gilbert C, Dodier S, Bataille V, Sudol M, Herlyn M, Mauviel A. Pro-Invasive Activity of the Hippo Pathway Effectors YAP and TAZ in Cutaneous Melanoma. The Journal of investigative dermatology. 2014;134:123–132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3938155</ArticleId>
            <ArticleId IdType="pubmed">23897276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen LT, Tretiakova MS, Silvis MR, Lucas J, Klezovitch O, Coleman I, Bolouri H, Kutyavin VI, Morrissey C, True LD, et al.  ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors. Cancer Cell. 2015;27:797–808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4461839</ArticleId>
            <ArticleId IdType="pubmed">26058078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noguchi S, Saito A, Horie M, Mikami Y, Suzuki HI, Morishita Y, Ohshima M, Abiko Y, Mattsson JS, Konig H, et al.  An integrative analysis of the tumorigenic role of TAZ in human non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014;20:4660–4672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24951773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nowell CS, Odermatt PD, Azzolin L, Hohnel S, Wagner EF, Fantner GE, Lutolf MP, Barrandon Y, Piccolo S, Radtke F. Chronic inflammation imposes aberrant cell fate in regenerating epithelia through mechanotransduction. Nature cell biology. 2015;18:168–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6195194</ArticleId>
            <ArticleId IdType="pubmed">26689676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Hayre M, Vazquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, Gutkind JS. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer. 2013;13:412–424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4068741</ArticleId>
            <ArticleId IdType="pubmed">23640210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh JE, Ohta T, Satomi K, Foll M, Durand G, McKay J, Le Calvez-Kelm F, Mittelbronn M, Brokinkel B, Paulus W, Ohgaki H. Alterations in the NF2/LATS1/LATS2/YAP Pathway in Schwannomas. J Neuropathol Exp Neurol. 2015;74:952–959.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26360373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orr BA, Bai H, Odia Y, Jain D, Anders RA, Eberhart CG. Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth. J Neuropathol Exp Neurol. 2011;70:568–577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3130608</ArticleId>
            <ArticleId IdType="pubmed">21666501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan D. The hippo signaling pathway in development and cancer. Developmental Cell. 2010;19:491–505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3124840</ArticleId>
            <ArticleId IdType="pubmed">20951342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan J, Li S, Chi P, Xu Z, Lu X, Huang Y. Lentivirus-mediated RNA interference targeting WWTR1 in human colorectal cancer cells inhibits cell proliferation in vitro and tumor growth in vivo. Oncology reports. 2012;28:179–185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22470139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park HW, Kim YC, Yu B, Moroishi T, Mo JS, Plouffe SW, Meng Z, Lin KC, Yu FX, Alexander CM, et al.  Alternative Wnt Signaling Activates YAP/TAZ. Cell. 2015;162:780–794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4538707</ArticleId>
            <ArticleId IdType="pubmed">26276632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearson HB, Perez-Mancera PA, Dow LE, Ryan A, Tennstedt P, Bogani D, Elsum I, Greenfield A, Tuveson DA, Simon R, Humbert PO. SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. J Clin Invest. 2011;121:4257–4267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3223862</ArticleId>
            <ArticleId IdType="pubmed">21965329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, Raschioni C, Testore E, Roncalli M, Giordano S, Columbano A. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014;61:1088–1096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25010260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiological reviews. 2014;94:1287–1312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25287865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pobbati AV, Han X, Hung AW, Weiguang S, Huda N, Chen GY, Kang C, Chia CS, Luo X, Hong W, Poulsen A. Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy. Structure. 2015;23:2076–2086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4660270</ArticleId>
            <ArticleId IdType="pubmed">26592798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rashidian J, Le Scolan E, Ji X, Zhu Q, Mulvihill MM, Nomura D, Luo K. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression. Science signaling. 2015;8:ra14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4457509</ArticleId>
            <ArticleId IdType="pubmed">25670202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reginensi A, Scott RP, Gregorieff A, Bagherie-Lachidan M, Chung C, Lim DS, Pawson T, Wrana J, McNeill H. Yap- and Cdc42-dependent nephrogenesis and morphogenesis during mouse kidney development. PLoS Genet. 2013;9:e1003380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3605093</ArticleId>
            <ArticleId IdType="pubmed">23555292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren F, Zhang L, Jiang J. Hippo signaling regulates Yorkie nuclear localization and activity through 14-3-3 dependent and independent mechanisms. Dev Biol. 2010;337:303–312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2812623</ArticleId>
            <ArticleId IdType="pubmed">19900439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romero-Perez L, Garcia-Sanz P, Mota A, Leskela S, Hergueta-Redondo M, Diaz-Martin J, Lopez-Garcia MA, Castilla MA, Martinez-Ramirez A, Soslow RA, et al.  A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2015;28:1492–1503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26381823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenbluh J, Nijhawan D, Cox AG, Li X, Neal JT, Schafer EJ, Zack TI, Wang X, Tsherniak A, Schinzel AC, et al.  beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012;151:1457–1473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3530160</ArticleId>
            <ArticleId IdType="pubmed">23245941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sansores-Garcia L, Bossuyt W, Wada K, Yonemura S, Tao C, Sasaki H, Halder G. Modulating F-actin organization induces organ growth by affecting the Hippo pathway. The EMBO journal. 2011;30:2325–2335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3116287</ArticleId>
            <ArticleId IdType="pubmed">21556047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D, Kreger BT, Vasioukhin V, Avruch J, Brummelkamp TR, Camargo FD. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell. 2011;144:782–795.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3237196</ArticleId>
            <ArticleId IdType="pubmed">21376238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serrano I, McDonald PC, Lock F, Muller WJ, Dedhar S. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nature communications. 2013;4 2976.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3905719</ArticleId>
            <ArticleId IdType="pubmed">24356468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, et al.  KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014;158:171–184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4110062</ArticleId>
            <ArticleId IdType="pubmed">24954536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheen-Chen SM, Huang CY, Tsai CH, Liu YW, Wu SC, Huang CC, Eng HL, Chan YC, Ko SF, Tang RP. Yes-associated protein is not an independent prognostic marker in breast cancer. Anticancer Res. 2012;32:3321–3325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22843909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen S, Guo X, Yan H, Lu Y, Ji X, Li L, Liang T, Zhou D, Feng XH, Zhao JC, et al.  A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis. Cell Res. 2015;25:997–1012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4559818</ArticleId>
            <ArticleId IdType="pubmed">26272168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheng X, Li WB, Wang DL, Chen KH, Cao JJ, Luo Z, He J, Li MC, Liu WJ, Yu C. YAP is closely correlated with castration-resistant prostate cancer, and downregulation of YAP reduces proliferation and induces apoptosis of PC-3 cells. Mol Med Rep. 2015;12:4867–4876.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4581809</ArticleId>
            <ArticleId IdType="pubmed">26126522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silvis MR, Kreger BT, Lien WH, Klezovitch O, Rudakova GM, Camargo FD, Lantz DM, Seykora JT, Vasioukhin V. alpha-catenin is a tumor suppressor that controls cell accumulation by regulating the localization and activity of the transcriptional coactivator Yap1. Science signaling. 2011;4:ra33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3366274</ArticleId>
            <ArticleId IdType="pubmed">21610251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skibinski A, Breindel JL, Prat A, Galvan P, Smith E, Rolfs A, Gupta PB, Labaer J, Kuperwasser C. The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell reports. 2014;6:1059–1072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4011189</ArticleId>
            <ArticleId IdType="pubmed">24613358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, Chen Y, Park O, Chang J, Simpson RM, et al.  Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A. 2010;107:1431–1436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2824397</ArticleId>
            <ArticleId IdType="pubmed">20080598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song M, Cheong JH, Kim H, Noh SH, Kim H. Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer. Anticancer Res. 2012;32:3827–3834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22993325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song Q, Mao B, Cheng J, Gao Y, Jiang K, Chen J, Yuan Z, Meng S. YAP enhances autophagic flux to promote breast cancer cell survival in response to nutrient deprivation. PLoS One. 2015a;10:e0120790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4374846</ArticleId>
            <ArticleId IdType="pubmed">25811979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song S, Ajani JA, Honjo S, Maru DM, Chen Q, Scott AW, Heallen TR, Xiao L, Hofstetter WL, Weston B, et al.  Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer Res. 2014;74:4170–4182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4136429</ArticleId>
            <ArticleId IdType="pubmed">24906622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, et al.  The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015b;21:2580–2590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4452384</ArticleId>
            <ArticleId IdType="pubmed">25739674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio R, Piazza S, et al.  Metabolic control of YAP and TAZ by the mevalonate pathway. Nature cell biology. 2014;16:357–366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24658687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stein C, Bardet AF, Roma G, Bergling S, Clay I, Ruchti A, Agarinis C, Schmelzle T, Bouwmeester T, Schubeler D, Bauer A. YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers. PLoS Genet. 2015;11:e1005465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4546604</ArticleId>
            <ArticleId IdType="pubmed">26295846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Striedinger K, VandenBerg SR, Baia GS, McDermott MW, Gutmann DH, Lal A. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia. 2008;10:1204–1212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2570596</ArticleId>
            <ArticleId IdType="pubmed">18953429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su LL, Ma WX, Yuan JF, Shao Y, Xiao W, Jiang SJ. Expression of Yes-associated protein in non-small cell lung cancer and its relationship with clinical pathological factors. Chin Med J (Engl) 2012;125:4003–4008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23158133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su T, Bondar T, Zhou X, Zhang C, He H, Medzhitov R. Two-signal requirement for growth-promoting function of Yap in hepatocytes. Elife. 2015;4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4363878</ArticleId>
            <ArticleId IdType="pubmed">25667983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene. 1994;9:2145–2152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8035999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanahashi K, Natsume A, Ohka F, Motomura K, Alim A, Tanaka I, Senga T, Harada I, Fukuyama R, Sumiyoshi N, et al.  Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness. J Neuropathol Exp Neurol. 2015;74:704–709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26049897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanas MR, Ma S, Jadaan FO, Ng CK, Weigelt B, Reis-Filho JS, Rubin BP. Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein. Oncogene. 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4983459</ArticleId>
            <ArticleId IdType="pubmed">25961935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland BS, Chang JT, et al.  A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015;519:57–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4447318</ArticleId>
            <ArticleId IdType="pubmed">25731159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao J, Calvisi DF, Ranganathan S, Cigliano A, Zhou L, Singh S, Jiang L, Fan B, Terracciano L, Armeanu-Ebinger S, et al.  Activation of beta-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology. 2014;147:690–701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4143445</ArticleId>
            <ArticleId IdType="pubmed">24837480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber D, Hariharan IK. salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell. 2002;110:467–478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12202036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian T, Li A, Lu H, Luo R, Zhang M, Li Z. TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells. Biochemical and biophysical research communications. 2015;463:638–643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26043698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian W, Yu J, Tomchick DR, Pan D, Luo X. Structural and functional analysis of the YAP-binding domain of human TEAD2. Proc Natl Acad Sci U S A. 2010;107:7293–7298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2867681</ArticleId>
            <ArticleId IdType="pubmed">20368466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tremblay AM, Missiaglia E, Galli GG, Hettmer S, Urcia R, Carrara M, Judson RN, Thway K, Nadal G, Selfe JL, et al.  The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. Cancer Cell. 2014;26:273–287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25087979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsujiura M, Mazack V, Sudol M, Kaspar HG, Nash J, Carey DJ, Gogoi R. Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer. PLoS One. 2014;9:e100974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4074125</ArticleId>
            <ArticleId IdType="pubmed">24972085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Keymeulen A, Lee MY, Ousset M, Brohee S, Rorive S, Giraddi RR, Wuidart A, Bouvencourt G, Dubois C, Salmon I, et al.  Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature. 2015;525:119–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26266985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verfaillie A, Imrichova H, Atak ZK, Dewaele M, Rambow F, Hulselmans G, Christiaens V, Svetlichnyy D, Luciani F, Van den Mooter L, et al.  Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nature communications. 2015;6 6683.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4403341</ArticleId>
            <ArticleId IdType="pubmed">25865119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vici P, Mottolese M, Pizzuti L, Barba M, Sperati F, Terrenato I, Di Benedetto A, Natoli C, Gamucci T, Angelucci D, et al.  The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. Oncotarget. 2014;5:9619–9625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4259424</ArticleId>
            <ArticleId IdType="pubmed">25294813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Virchow R.  Die cellularpathologie in ihrer begründung auf physiologische und pathologische gewebelehre. Berlin: A. Hirschwald; 1858. </Citation>
        </Reference>
        <Reference>
          <Citation>Wada K, Itoga K, Okano T, Yonemura S, Sasaki H. Hippo pathway regulation by cell morphology and stress fibers. Development. 2011;138:3907–3914.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21831922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, Fang Z, Zhao K, Konaparthi R, Hua S, et al.  Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. Cancer Discov. 2016;6:80–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4707102</ArticleId>
            <ArticleId IdType="pubmed">26701088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Shi S, Guo Z, Zhang X, Han S, Yang A, Wen W, Zhu Q. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One. 2013a;8:e65539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3677905</ArticleId>
            <ArticleId IdType="pubmed">23762387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q, Xu Z, An Q, Jiang D, Wang L, Liang B, Li Z. TAZ promotes epithelial to mesenchymal transition via the upregulation of connective tissue growth factor expression in neuroblastoma cells. Mol Med Rep. 2015a;11:982–988.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4262480</ArticleId>
            <ArticleId IdType="pubmed">25354978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Xiao ZD, Li X, Aziz KE, Gan B, Johnson RL, Chen J. AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nature cell biology. 2015b;17:490–499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4380807</ArticleId>
            <ArticleId IdType="pubmed">25751139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Su L, Ou Q. Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. Eur J Cancer. 2012;48:1227–1234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22056638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Dong Q, Zhang Q, Li Z, Wang E, Qiu X. Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci. 2010;101:1279–1285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20219076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Xie C, Li Q, Xu K, Wang E. Clinical and prognostic significance of Yes-associated protein in colorectal cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013b;34:2169–2174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23558963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Wu Y, Wang H, Zhang Y, Mei L, Fang X, Zhang X, Zhang F, Chen H, Liu Y, et al.  Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci U S A. 2014;111:E89–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3890879</ArticleId>
            <ArticleId IdType="pubmed">24367099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu S, Huang J, Dong J, Pan D. hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell. 2003;114:445–456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12941273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia Y, Chang T, Wang Y, Liu Y, Li W, Li M, Fan HY. YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PLoS One. 2014;9:e91770.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3951505</ArticleId>
            <ArticleId IdType="pubmed">24622501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao H, Jiang N, Zhou B, Liu Q, Du C. TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma. Cancer Sci. 2015;106:151–159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4399022</ArticleId>
            <ArticleId IdType="pubmed">25495189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao H, Wu L, Zheng H, Li N, Wan H, Liang G, Zhao Y, Liang J. Expression of Yes-associated protein in cervical squamous epithelium lesions. Int J Gynecol Cancer. 2014;24:1575–1582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25304677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao W, Wang J, Ou C, Zhang Y, Ma L, Weng W, Pan Q, Sun F. Mutual interaction between YAP and c-Myc is critical for carcinogenesis in liver cancer. Biochemical and biophysical research communications. 2013;439:167–172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23994632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie M, Zhang L, He CS, Hou JH, Lin SX, Hu ZH, Xu F, Zhao HY. Prognostic significance of TAZ expression in resected non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012;7:799–807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22481233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, Chen J, Poon RT, Zender L, Lowe SW, Hong W, Luk JM. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene. 2011;30:1229–1240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3330262</ArticleId>
            <ArticleId IdType="pubmed">21076472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT, Luk JM. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009;115:4576–4585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2811690</ArticleId>
            <ArticleId IdType="pubmed">19551889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu T, Wang W, Zhang S, Stewart RA, Yu W. Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development. 1995;121:1053–1063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7743921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang S, Zhang L, Purohit V, Shukla SK, Chen X, Yu F, Fu K, Chen Y, Solheim J, Singh PK, et al.  Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. Oncotarget. 2015;6:36019–36031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4742158</ArticleId>
            <ArticleId IdType="pubmed">26440309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeo MK, Kim SH, Kim JM, Huang SM, Kim MR, Song KS, Kim KH. Correlation of expression of phosphorylated and non-phosphorylated Yesassociated protein with clinicopathological parameters in esophageal squamous cell carcinoma in a Korean population. Anticancer Res. 2012;32:3835–3840.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22993326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yimlamai D, Christodoulou C, Galli GG, Yanger K, Pepe-Mooney B, Gurung B, Shrestha K, Cahan P, Stanger BZ, Camargo FD. Hippo pathway activity influences liver cell fate. Cell. 2014;157:1324–1338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4136468</ArticleId>
            <ArticleId IdType="pubmed">24906150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin F, Yu J, Zheng Y, Chen Q, Zhang N, Pan D. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell. 2013;154:1342–1355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3835333</ArticleId>
            <ArticleId IdType="pubmed">24012335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, Zhao L, Peyman G, Ouyang H, Jiang W, et al.  Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell. 2014;25:822–830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4075337</ArticleId>
            <ArticleId IdType="pubmed">24882516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, et al.  Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012;150:780–791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3433174</ArticleId>
            <ArticleId IdType="pubmed">22863277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, Gangeswaran R, Manson-Bishop C, Smith P, Danovi SA, et al.  Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell death and differentiation. 2008;15:1752–1759.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18617895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yue G, Sun X, Gimenez-Capitan A, Shen J, Yu L, Teixido C, Guan W, Rosell R, Liu B, Wei J. TAZ is highly expressed in gastric signet ring cell carcinoma. Biomed Res Int. 2014;2014 393064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3953576</ArticleId>
            <ArticleId IdType="pubmed">24707483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuen HF, McCrudden CM, Huang YH, Tham JM, Zhang X, Zeng Q, Zhang SD, Hong W. TAZ expression as a prognostic indicator in colorectal cancer. PLoS One. 2013;8:e54211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3553150</ArticleId>
            <ArticleId IdType="pubmed">23372686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanconato F, Forcato M, Battilana G, Azzolin L, Quaranta E, Bodega B, Rosato A, Bicciato S, Cordenonsi M, Piccolo S. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nature cell biology. 2015;17:1218–1227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6186417</ArticleId>
            <ArticleId IdType="pubmed">26258633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanconato F, Piccolo S. Eradicating tumor drug resistance at its YAP-biomechanical roots. The EMBO journal. 2015 doi: 10.15252/embj.201593584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embj.201593584</ArticleId>
            <ArticleId IdType="pmc">PMC4772852</ArticleId>
            <ArticleId IdType="pubmed">26711176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, et al.  Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006;125:1253–1267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3026384</ArticleId>
            <ArticleId IdType="pubmed">16814713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhan L, Rosenberg A, Bergami KC, Yu M, Xuan Z, Jaffe AB, Allred C, Muthuswamy SK. Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell. 2008;135:865–878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3015046</ArticleId>
            <ArticleId IdType="pubmed">19041750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Yang S, Chen X, Stauffer S, Yu F, Lele SM, Fu K, Datta K, Palermo N, Chen Y, Dong J. The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells. Mol Cell Biol. 2015a;35:1350–1362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4372700</ArticleId>
            <ArticleId IdType="pubmed">25645929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J, Giovannini M, Liu P, Anders RA, Pan D. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell. 2010;19:27–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2925178</ArticleId>
            <ArticleId IdType="pubmed">20643348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W, Gao Y, Li F, Tong X, Ren Y, Han X, Yao S, Long F, Yang Z, Fan H, et al.  YAP Promotes Malignant Progression of Lkb1-Deficient Lung Adenocarcinoma through Downstream Regulation of Survivin. Cancer Res. 2015b;75:4450–4457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26363011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W, Gao Y, Li P, Shi Z, Guo T, Li F, Han X, Feng Y, Zheng C, Wang Z, et al.  VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res. 2014a;24:331–343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3945886</ArticleId>
            <ArticleId IdType="pubmed">24458094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ, Wadhwa M, et al.  Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Science signaling. 2014b;7:ra42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4175524</ArticleId>
            <ArticleId IdType="pubmed">24803537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB, group AS. Bowtell DD, Harvey KF. The Hippo pathway transcriptional coactivator, YAP, is an ovarian cancer oncogene. Oncogene. 2011;30:2810–2822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21317925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang YH, Li B, Shen L, Shen Y, Chen XD. The role and clinical significance of YES-associated protein 1 in human osteosarcoma. Int J Immunopathol Pharmacol. 2013;26:157–167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23527718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes &amp; development. 2012;26:54–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3258966</ArticleId>
            <ArticleId IdType="pubmed">22215811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, et al.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes &amp; development. 2007;21:2747–2761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2045129</ArticleId>
            <ArticleId IdType="pubmed">17974916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, et al.  TEAD mediates YAP-dependent gene induction and growth control. Genes &amp; development. 2008;22:1962–1971.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2492741</ArticleId>
            <ArticleId IdType="pubmed">18579750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J, Bardeesy N. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell. 2009;16:425–438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3023165</ArticleId>
            <ArticleId IdType="pubmed">19878874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou D, Zhang Y, Wu H, Barry E, Yin Y, Lawrence E, Dawson D, Willis JE, Markowitz SD, Camargo FD, Avruch J. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci U S A. 2011a;108:E1312–1320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3241824</ArticleId>
            <ArticleId IdType="pubmed">22042863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS, Yang X. TAZ is a novel oncogene in non-small cell lung cancer. Oncogene. 2011b;30:2181–2186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21258416</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
